Human mutations that confer paclitaxel resistance

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Clinical drug resistance in cancer therapy is a significant challenge.
• Tubulin mutations are a suspected cause of resistance to microtubule-targeting drugs.
• Beta1-tubulin is a critical component of microtubules and a target for chemotherapy.

Purpose of the Study:

• To investigate whether specific beta1-tubulin mutations and polymorphisms found in cancer patients confer resistance to paclitaxel.
• To elucidate the mechanism by which beta1-tubulin mutations affect drug sensitivity and microtubule function.

Main Methods:

• Utilized transfection to introduce specific beta1-tubulin mutations into cancer cells.
• Selected cells in paclitaxel to identify resistant clones.
• Assessed paclitaxel resistance by measuring cell survival and transgene expression.
• Analyzed the impact of mutations on microtubule assembly, mitotic progression, and sensitivity to other microtubule-disruptive agents.

Main Results:

• Three of four tested beta1-tubulin mutations (A185T, A248V, R306C) conferred significant paclitaxel resistance.
• Paclitaxel resistance was directly correlated with the expression level of mutant beta1-tubulin.
• Mutations disrupted microtubule assembly, impaired mitosis, and increased sensitivity to other microtubule-disruptive drugs.
• The G437S mutation did not confer paclitaxel resistance.

Conclusions:

• Human tumor cells can acquire spontaneous beta1-tubulin mutations that lead to paclitaxel resistance.
• Beta1-tubulin mutations likely confer resistance by altering microtubule stability, counteracting paclitaxel's mechanism of action.
• Patients with certain beta1-tubulin polymorphisms may require adjusted paclitaxel dosing for optimal therapeutic outcomes.